Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Taiwan launches genetic map for bile duct cancer

NCT ID NCT05036486

Knowledge-focused Sponsor: National Health Research Institutes, Taiwan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study collects tumor tissue from 480 people with advanced biliary tract cancer in Taiwan to analyze their genetic makeup. The goal is to create a detailed map of genetic changes in this cancer, which could help identify potential targeted therapies. Participants are already receiving or about to start their first standard treatment, and the study simply observes and records their genetic and clinical data.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could create a detailed genetic map of biliary tract cancer in Taiwan, helping doctors match patients with targeted treatments in the future.
What could go wrong
This is an observational registry, not a treatment trial. It will not directly benefit participants and may not lead to new therapies for years, if at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

480 people

The number who actually took part.

Started

Oct 2021

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

ready to have 1st systemic treatment or under 1st line therapy therapy, metastatic or unresectable population s , clinical information , and therapeutic outcomes in advanced BTC

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Ages 20 and above. 2. Pathological reported showed adenocarcinoma or adenosquamous carcinoma for patients with BTC (include IHCC, EHCC, GBC or AVC) or hepatocholangiocarcinoma as locally advanced or metastatic status. 3. Willingness to provide the residual biopsy/operative slides. 4. Life expectancy more than 3 months. 5. Patients fully understand the protocol with the willingness to have regular follow-up. 6. Patients are ready to have 1st systemic treatment or under 1st line therapy 7. Total bilirubin ≦5 mg/dL, and ECOG≦2 Exclusion Criteria: 1. Inability to cooperate by providing a complete medical history. 2. No available tumor tissues for genetic testing. 3. Undesirable compliance. 4. Other malignancy within the past 1 years except adequately treated basal or squamous cell skin cancer or cervical cancer in situ.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biliary tract cancer (BTC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biliary tract cancer (BTC)

Contacts and locations

Locations

  • Chang Gung Memorial Hospital, Chiayi

    Chiayi City, Taiwan

  • China Medical University Hospital

    Taichung, Taiwan

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital,

    Kaohsiung City, Taiwan

  • Koo Foundation Sun Yat-Sen Cancer Center

    Taipei, Taiwan

  • Linko Chang Gung Memorial Hospital

    Taoyuan, Taiwan

  • MacKay Memorial Hospital

    Taipei, Taiwan

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taipei Medical University-Shuang Ho Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Taoyuan General Hospital, Ministry of Health and Welfare

    Taoyuan, Taiwan

  • Tri-Service General Hospital

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.